Catalog No.
Product Name
Application
Product Information
Product Citation
-
Proton pump inhibitor
Esomeprazole sodium is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 uM. -
Proton pump inhibitor
Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. - M2 ion channel blocker is capable of inhibiting and blocking the activity of M2 ion channel. Antiviral agents.
-
proton pump inhibitor
Rabeprazole sodium is an antiulcer drug in the class of proton pump inhibitors. - Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
-
Proton pump inhibitor
Lauric acid is a proton pump inhibitor potentially for the treatment of helicobacter pylori infections. -
proton pump inhibitor
(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM. -
H(+)-K(+)-exchanging ATPase inhibitor
Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole sodium(AG-1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138. -
gastric H+/K+ ATPase inhibitor
Soraprazan is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase. -
Proton Pump inhibitor
Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. -
gastric H+/K+-ATPase inhibitor
Tegoprazan, a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. -
H+/K+-ATPase inhibitor
Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1??0.4 μM.
